WO2000056774A8 - Methods of using bioelastomers - Google Patents

Methods of using bioelastomers

Info

Publication number
WO2000056774A8
WO2000056774A8 PCT/US2000/005780 US0005780W WO0056774A8 WO 2000056774 A8 WO2000056774 A8 WO 2000056774A8 US 0005780 W US0005780 W US 0005780W WO 0056774 A8 WO0056774 A8 WO 0056774A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compound
bioelastomers
bioelastomer
biosensors
Prior art date
Application number
PCT/US2000/005780
Other languages
French (fr)
Other versions
WO2000056774A1 (en
WO2000056774A9 (en
Inventor
Ashutosh Chilkoti
Original Assignee
Univ Duke
Ashutosh Chilkoti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Ashutosh Chilkoti filed Critical Univ Duke
Priority to AU38674/00A priority Critical patent/AU3867400A/en
Publication of WO2000056774A1 publication Critical patent/WO2000056774A1/en
Publication of WO2000056774A8 publication Critical patent/WO2000056774A8/en
Publication of WO2000056774A9 publication Critical patent/WO2000056774A9/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)

Abstract

Bioelastomers are disclosed for use in methods of binding compounds including immunoassay methods, in biosensors and methods or regenerating biosensors, and in methods for targeting the delivery of a compound to a particular location within animal subjects. In general, the bioelastomer is conjugated to a binding compound, which is in turn used to bind a compound of interest. For targeted compound delivery, the bioelastomer is conjugated to the compound to be delivered.
PCT/US2000/005780 1999-03-19 2000-03-06 Methods of using bioelastomers WO2000056774A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38674/00A AU3867400A (en) 1999-03-19 2000-03-06 Methods of using bioelastomers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27302599A 1999-03-19 1999-03-19
US09/273,025 1999-03-19

Publications (3)

Publication Number Publication Date
WO2000056774A1 WO2000056774A1 (en) 2000-09-28
WO2000056774A8 true WO2000056774A8 (en) 2001-05-03
WO2000056774A9 WO2000056774A9 (en) 2002-06-20

Family

ID=23042233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005780 WO2000056774A1 (en) 1999-03-19 2000-03-06 Methods of using bioelastomers

Country Status (3)

Country Link
US (4) US6582926B1 (en)
AU (1) AU3867400A (en)
WO (1) WO2000056774A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US7087244B2 (en) 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
WO2000056774A1 (en) * 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US20040115830A1 (en) * 2002-09-25 2004-06-17 Igor Touzov Components for nano-scale Reactor
TWI354021B (en) * 2002-12-23 2011-12-11 Alcon Inc Compositions and methods for inhibiting protein on
AU2003902483A0 (en) * 2003-05-21 2003-06-05 Commonwealth Scientific And Industrial Research Organisation A bioelastomer ii
US20050053949A1 (en) * 2003-09-08 2005-03-10 Silin Vitalii Ivanovich Biochip for proteomics applications
CN101437856A (en) * 2004-10-14 2009-05-20 塔夫茨大学信托人 Electrochemically degradable polymers
KR101446503B1 (en) * 2005-06-24 2014-10-06 듀크 유니버시티 Direct drug delivery system based on thermally responsive biopolymers
ES2638792T3 (en) * 2005-07-28 2017-10-24 Carbon Sink Inc. Removal of carbon dioxide from the air
US7713689B2 (en) * 2005-09-15 2010-05-11 Duke University Non-fouling polymeric surface modification and signal amplification method for biomolecular detection
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ES2779992T3 (en) * 2005-12-20 2020-08-21 Univ Duke Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US9682118B1 (en) * 2006-01-27 2017-06-20 University Of Mississippi Medical Center Inhibition of metastasis by cell penetrating peptides
US20070184501A1 (en) * 2006-02-07 2007-08-09 Beckman Coulter, Inc. Blocker reagent for reduction of heterophile interferences
EP1873205A1 (en) * 2006-06-12 2008-01-02 Corning Incorporated Thermo-responsive blends and uses thereof
FR2902799B1 (en) 2006-06-27 2012-10-26 Millipore Corp METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID
US20100189643A1 (en) * 2006-07-24 2010-07-29 Duke University Drug delivery with stimulus responsive biopolymers
WO2008024311A2 (en) * 2006-08-22 2008-02-28 Duke University Purification of low-abundant recombinant proteins from cell culture
AU2007321701B2 (en) * 2006-11-13 2012-08-30 Allergan Pharmaceuticals International Limited Use of tropoelastin for repair or restoration of tissue
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
DE102007044708A1 (en) * 2007-09-18 2009-03-19 Eads Deutschland Gmbh Apparatus and method for regenerating biosensors
US8796184B2 (en) 2008-03-28 2014-08-05 Sentilus, Inc. Detection assay devices and methods of making and using the same
US8999702B2 (en) * 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
WO2010014689A1 (en) * 2008-07-29 2010-02-04 Phasebio Pharmaceuticals, Inc. Pharmaceutical formulations comprising elastin-like proteins
SG171446A1 (en) * 2008-12-16 2011-07-28 Millipore Corp Stirred tank reactor and method
EP2464370B1 (en) * 2009-08-14 2017-03-29 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
US8603303B2 (en) 2010-03-15 2013-12-10 International Business Machines Corporation Nanopore based device for cutting long DNA molecules into fragments
SG10201804385YA (en) 2010-05-17 2018-06-28 Emd Millipore Corp Stimulus responsive polymers for the purification of biomolecules
US20110301456A1 (en) * 2010-06-07 2011-12-08 Malignext Targeting Technologies, Inc. Tissue Marking for Lesion Removal
CN101955960B (en) * 2010-08-03 2012-05-23 中山大学 Method for purifying recombinant lactase by using elastin like protein tag
US8470967B2 (en) 2010-09-24 2013-06-25 Duke University Phase transition biopolymers and methods of use
US8986524B2 (en) 2011-01-28 2015-03-24 International Business Machines Corporation DNA sequence using multiple metal layer structure with different organic coatings forming different transient bondings to DNA
US20120193231A1 (en) * 2011-01-28 2012-08-02 International Business Machines Corporation Dna sequencing using multiple metal layer structure with organic coatings forming transient bonding to dna bases
US8852407B2 (en) 2011-01-28 2014-10-07 International Business Machines Corporation Electron beam sculpting of tunneling junction for nanopore DNA sequencing
ES2669190T3 (en) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US10029915B2 (en) 2012-04-04 2018-07-24 International Business Machines Corporation Functionally switchable self-assembled coating compound for controlling translocation of molecule through nanopores
EP2657681A1 (en) 2012-04-26 2013-10-30 Roche Diagnostics GmbH Improvement of the sensitivity and the dynamic range of photometric assays by generating multiple calibration curves
US9046511B2 (en) 2013-04-18 2015-06-02 International Business Machines Corporation Fabrication of tunneling junction for nanopore DNA sequencing
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US9182369B2 (en) 2013-06-19 2015-11-10 Globalfoundries Inc. Manufacturable sub-3 nanometer palladium gap devices for fixed electrode tunneling recognition
US9188578B2 (en) 2013-06-19 2015-11-17 Globalfoundries Inc. Nanogap device with capped nanowire structures
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US10722590B2 (en) 2014-11-21 2020-07-28 Phasebio Pharmaceuticals, Inc. ELP fusion proteins for controlled and sustained release
CN114652817A (en) 2015-02-09 2022-06-24 费斯生物制药公司 Methods and compositions for treating muscle diseases and disorders
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
EP3331557B1 (en) 2015-08-04 2021-04-07 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
EP4043010A1 (en) 2016-05-06 2022-08-17 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
US10542807B2 (en) 2016-06-30 2020-01-28 Helen Of Troy Limited Multi-function actuator for adjusting two or more hair appliance variables
EP3512868A4 (en) 2016-09-14 2020-04-15 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
JP2020500150A (en) 2016-09-23 2020-01-09 デューク ユニバーシティ Non-repetitive and non-structural polypeptides with lower critical solution temperature behavior
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
CA3109082A1 (en) 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021168270A1 (en) 2020-02-19 2021-08-26 Isolere Bio, Inc. Protein-based purification matrices and methods of using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474851A (en) * 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4752638A (en) 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4749647A (en) 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
US5770697A (en) * 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US6184348B1 (en) * 1986-11-04 2001-02-06 Protein Polymer Technologies Functional recombinantly prepared synthetic protein polymer
US5243038A (en) * 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5606019A (en) * 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ES2067150T3 (en) * 1990-03-27 1995-03-16 Bioelastics Res Ltd BIOELASTOMERIC DRUG SUPPLY SYSTEM.
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5900405A (en) * 1994-01-24 1999-05-04 Bioelastics Research, Ltd. Polymers responsive to electrical energy
US5527610A (en) * 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
US6004782A (en) 1995-04-14 1999-12-21 Bioelastics Research Ltd. Hyperexpression of bioelastic polypeptides
US5854387A (en) * 1995-04-14 1998-12-29 Bioelastics Research, Ltd. Simple method for the purification of a bioelastic polymer
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
DE69620898T2 (en) * 1995-09-01 2002-11-07 Univ Washington Seattle INTERACTIVE MOLECULAR CONJUGATES
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5816259A (en) * 1997-01-13 1998-10-06 Rose; Samuel Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
CA2319558A1 (en) * 1998-02-27 1999-09-02 Bioelastics Research, Ltd. Injectable implants for tissue augmentation and restoration
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000056774A1 (en) * 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US6852834B2 (en) * 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition

Also Published As

Publication number Publication date
WO2000056774A1 (en) 2000-09-28
US6582926B1 (en) 2003-06-24
US20030059841A1 (en) 2003-03-27
AU3867400A (en) 2000-10-09
US7429458B2 (en) 2008-09-30
US20090270317A1 (en) 2009-10-29
US7364859B2 (en) 2008-04-29
WO2000056774A9 (en) 2002-06-20
US20030059840A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
WO2000056774A8 (en) Methods of using bioelastomers
EP1046394A3 (en) Novel compositions useful for delivering compounds into a cell
WO2003059251A3 (en) Antibody targeting compounds
WO2005003316A3 (en) Rna processing protein complexes and uses thereof
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
EP1789447A4 (en) Method of delivering rna interference and uses thereof
AU2001288249A1 (en) Biosensors and methods for their use
WO2008136869A3 (en) Methods and compositions related to targeting wounds, regenerating tissue, and tumors
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2001039777A8 (en) Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
WO2004083369A3 (en) Tissue binding composition
AU5076799A (en) Trifunctional reagent for conjugation to a biomolecule
CA2371857A1 (en) Gardos channel antagonists
EP1300119A3 (en) A device for detecting the condition of heat on an animal, a positioning device, a stable provided with a positioning device and a method of detecting a condition of heat
HUP0105302A3 (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation
WO2002087497A3 (en) Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
AU2003302165A1 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO2004021996A3 (en) Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same
EP1420066A3 (en) Use of fullerene derivatives as DNA compaction agent
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
ZA982136B (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer.
WO2001085188A3 (en) Use of echinacea as a hematinic agent
EP1023906A4 (en) Potentiator for antibody against lymphoid tumor
WO2001019871A3 (en) Delivery system for antidandruff agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 39/2000 UNDER (81) ADD "CR, DM, GD, MA"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase